Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) announced on Friday that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It follows the successful completion of the ADHERE clinical trial, which demonstrated VYVDURA's efficacy and safety in treating CIDP.

VYVDURA is approved for once-weekly subcutaneous self-administration at home, offering a convenient treatment option for patients.

Earlier this year VYVDURA was approved for the treatment of generalised myasthenia gravis (gMG) in Japan.

CIDP is a rare and debilitating neurological disorder with limited treatment options.

VYVDURA is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP in Japan.